Elbit Imaging Ltd. announced that Gamida Cell Ltd. has announced that new data from its clinical programs will be presented at the 2019 Transplantation & Cellular Therapy (TCT) Meeting of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place in Houston, Texas, February 20–24. Initial results indicating clinical response and a safe profile of the ongoing Phase I study of patients with relapsed or refractory non-Hodgkin lymphoma and multiple myeloma treated with NAM-expanded Natural Killer cells. The study is led by the University of Minnesota. Results demonstrating rapid immune reconstitution in patients transplanted with NiCord, as part of a Phase I/II clinical study of hematological malignancies. The study is led by the Memorial Sloan Kettering Center. Initial results indicating prompt cord engraftment and proper graft function in Phase I/II clinical study of severe aplastic anemia using NiCord (formerly: CordIn). The study is led by the National Institutes of Health. It should be noted that patient enrollment continues in the NAM-NK study of multiple myeloma and non-Hodgkin lymphoma (NHL), and in the study of severe aplastic anemia using NiCord.